EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Milestone Pharmaceuticals's Enterprise Value is $112.08 Mil.
Milestone Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was $-28.85 Mil. Therefore, Milestone Pharmaceuticals's EV-to-FCF for today is -3.89.
The historical rank and industry rank for Milestone Pharmaceuticals's EV-to-FCF or its related term are showing as below:
MIST'
s EV-to-FCF Range Over the Past 10 Years
Min: -8.07 Med: -1.99 Max: -0.92
Current: -3.94
During the past 8 years, the highest EV-to-FCF of Milestone Pharmaceuticals was -0.92. The lowest was -8.07. And the median was -1.99.
MIST's EV-to-FCF is ranked worse than 100% of 415
companies
in the Biotechnology industry
Industry Median: 4.08
vs MIST: -3.94
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Milestone Pharmaceuticals's EV-to-FCF
For the Biotechnology subindustry, Milestone Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Milestone Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Milestone Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Milestone Pharmaceuticals's EV-to-FCF falls into.
Milestone Pharmaceuticals's current Enterprise Value is $112.08 Mil.
Milestone Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-28.85 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Milestone Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Milestone Pharmaceuticals's share price for today is $1.99.
Milestone Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.680.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Milestone Pharmaceuticals EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Milestone Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MIST has been successfully added to your 